Why Cogent Biosciences, Inc. (COGT) stock moved
Cogent Biosciences, Inc. (COGT) shares tumbled 5.7% to $28.09 as of October 14, 2026, a significant decline from the prior close of $29.78. BestStocks flagged the session as a major change for COGT. Below, we break down what changed for COGT, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
COGT fell 5.7% to $28.09
Cogent Biosciences fell 6.5% on August 28, 2026, as investors digested Q2 earnings showing a widened net loss of $96.4 million (versus $73.5 million year-over-year) amid rising costs for pivotal clinical trials and commercial preparation of lead candidate bezuclastinib. The decline also reflected typical post-announcement profit-taking following the company's recent NDA submissions, including the FDA's acceptance of bezuclastinib with a target decision date in late December 2026, alongside dilution concerns from a $400 million stock prospectus filing.
What it means for Cogent Biosciences, Inc. investors
For Cogent Biosciences, Inc. investors, the recent signals add up to a bearish shift. On the constructive side: Cogent Biosciences, Inc. (COGT) moved +7.96% from $39.68 to $42.84 on 2026-08-04, reaching a new 30-day high on volume 3.3x the 5-day average. Weighing against that: Material negative event; Sharp 5.7% decline — elevated risk. Wall Street's consensus price target sits at $51.75, implying +84.2% upside from $28.09. BestStocks rates the overall signal quality medium (61/100). With earnings roughly 23 days out, the next report is the most likely near-term test of the move.
COGT price reaction
COGT last traded at $28.09, down $1.69 (-5.67%) from the previous close of $29.78. The session traded on 1.3× average volume (normal), so participation was unremarkable. Over the past month the stock has ranged between $28.09 and $33.41, and it currently sits about 0% of the way up that band.
Bullish and bearish analyst opinions on Cogent Biosciences, Inc. (COGT)
The consensus analyst price target on Cogent Biosciences, Inc. (COGT) is $51.75, 84.2% above the recent $28.09. Over the past 90 days analysts logged 0 upgrades, 4 maintains, and 0 downgrades. Here is how the bullish and bearish cases on COGT line up.
The bullish case
- Wall Street's consensus price target of $51.75 implies +84.2% upside from $28.09.
- The Street's most bullish target is $55.00 (+95.8%).
- Cogent Biosciences, Inc. (COGT) moved +7.96% from $39.68 to $42.84 on 2026-08-04, reaching a new 30-day high on volume 3.3x the 5-day average.
The bearish case
- Material negative event.
- Sharp 5.7% decline — elevated risk.
- Cogent Biosciences filed a material event (8-K) and earnings report today, triggering a 6.12% intraday decline to $38.99.
Weighing both sides, BestStocks' composite read of recent signals is bearish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Oct 14, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for COGT
In-depth COGT event analyses
Frequently asked questions about COGT
Why did Cogent Biosciences, Inc. (COGT) stock move?
Cogent Biosciences fell 6.5% on August 28, 2026, as investors digested Q2 earnings showing a widened net loss of $96.4 million (versus $73.5 million year-over-year) amid rising costs for pivotal clinical trials and commercial preparation of lead candidate bezuclastinib. The decline also reflected typical post-announcement profit-taking following the company's recent NDA submissions, including the FDA's acceptance of bezuclastinib with a target decision date in late December 2026, alongside dilution concerns from a $400 million stock prospectus filing.
How much did COGT stock fall?
COGT lost 5.67% ($1.69) versus the prior close of $29.78, last trading at $28.09 on 1.3× average volume.
When is Cogent Biosciences, Inc.'s next earnings date?
COGT's next earnings report is estimated for 2026-11-06 — about 23 days away.
What is the analyst price target for COGT?
The consensus analyst price target for COGT is $51.75, about 84.2% above the current $28.09. Over the past 90 days, analysts recorded 0 upgrades, 4 maintains, and 0 downgrades.
How BestStocks tracks COGT
This page is generated automatically by BestStocks' change-detection system after its price and volume cleared COGT-specific materiality thresholds, triggering an evidence check. It draws on 20 tracked change events for COGT, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of October 14, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.